Releases - Probi

View:
 

Found press releases

 

Probi´s Annual General Meeting 2013

4/24/2013 11:15 AM EST
On Probi´s Annual General Meeting on 24 April, 2013, the following was resolved:

· The Annual General Meeting approved the Annual Report and the Boards proposal for a dividend for the financial year 2012 corresponding to 0.75 SEK per share.The record date was set for April 29, 2013.
· The Annual General Meeting discharged the Board and the CEO from liability for the financial year 2012.
· The board shall consist...

GOOD START TO 2013

4/24/2013 5:25 AM EST
FIRST QUARTER 2013
• NET SALES amounted to MSEK 25.4 (30.6). Net sales for 2012 included minimum royalties of MSEK 3.8 from NextFoods pursuant to the agreement applicable then.
• OPERATING PROFIT totalled MSEK 6.0 (8.5). Operating profit for 2012 included minimum royalties of MSEK 3.8 from NextFoods pursuant to the agreement applicable then.
• PROFIT AFTER TAX amounted to MSEK 4.9 (6.4).
• PROFIT AFTER TAX PER SHARE...

Probi and NextFoods strengthen their GoodBelly® partnership in the USA

2/19/2013 3:15 AM EST
Probi and US food company NextFoods are strengthening their partnership on the North American market through a revised agreement which will run until 2020, with an option of further extension. This involves closer collaboration, a higher level of royalties for Probi starting from 1 July 2014, and prominent placement on GoodBelly® packaging and in advertising of the Probi Digestis® brand.

”The revised agreement is a...

OPERATING REVENUE EXCEEDED MSEK 100 WITH CONTINUED HEALTHY PROFITABILITY

1/24/2013 4:09 AM EST
FOURTH QUARTER OF 2012

· TOTAL OPERATING REVENUE amounted to MSEK 26.3 (24.7).
· NET SALES amounted to MSEK 26.2 (24.6).
· OPERATING PROFIT totalled MSEK 2.6 (loss: 0.7).
· PROFIT AFTER TAX amounted to MSEK 2.1 (loss: 0.3).
· PROFIT AFTER TAX PER SHARE was SEK 0.24 (loss: 0.03).
· CASH FLOW amounted to MSEK 1.2 (neg: 0.7).

FULL-YEAR 2012

· TOTAL OPERATING REVENUE amounted to MSEK 100.4 (95.0).
· NET SALES...

Symrise and Probi sign joint research and development agreement

12/20/2012 2:00 AM EST
Probi has signed a research and development agreement with the German company Symrise, a leading manufacturer of flavours, fragrances, cosmetics and health ingredients. In response to a growing consumer interest, the companies have decided to jointly develop innovative probiotic products with documented health benefits. The cooperation will initially focus on oral...

Probi and Viva 5 Corporation form Probiotic Business Development Alliance in Nor...

12/11/2012 2:45 AM EST
Probi has signed a business development agreement with Viva 5, a US probiotic specialist, granting them license rights within Consumer Healthcare for Probi Digestis®and Probi Defendum®in North America. Probi will work with Viva 5 to further strengthen its commercial position as well as the presence and consumer awareness of the Probi brand in the North American market place. Viva 5 and Probi are already engaged in...

Results from Probi’s Clinical Studies in Immune and Gut Health

11/29/2012 2:45 AM EST
The results from Probi’s two clinical studies conducted in 2012, one in immune health and one in gut health, are now available. Preliminary analyses of the data show that the results from the studies did not meet expectations. Probi will consequently not apply to the European Food Safety Authority (EFSA) for health claims within the EU at this point.

”We have gained important new knowledge from the studies and the...

Nomination Committee at Probi AB

10/24/2012 2:30 AM EST
Probi’s Nomination Committee prior to the 2013 Annual General Meeting comprises the following individuals:
Heinz-Jürgen Bertram, Symrise
Erik Sjöström, Skandia
Bengt Jeppsson, Professor in the surgery unit, Lund University

Erik Sjöström and Bengt Jeppsson were appointed at Probi’s Annual General Meeting on 26 April 2012. Heinz-Jürgen Bertram, CEO Symrise, replaces Ragnhild Wiborg, Consepio, pursuant to the policy...

FULL-YEAR GROWTH DESPITE DECLINE FOR PROVIVA

10/18/2012 5:13 AM EST
Third quarter of 2012

•    NET SALES amounted to MSEK 20.8 (21.9).

•    OPERATING PROFIT totalled MSEK 4.0 (5.5).

•    PROFIT AFTER TAX amounted to MSEK 2.9 (4.5).

•    PROFIT AFTER TAX PER SHARE was SEK 0.32 (0.49).

•    CASH FLOW amounted to MSEK 2.8 (neg: 1.8).   

Accumulated 2012

•    NET SALES amounted to MSEK 73.4 (69.8).

•    OPERATING PROFIT totalled MSEK 14.6 (18.5).

•    PROFIT AFTER TAX amounted...

Probi gains new industrial shareholder in Symrise of Germany

8/31/2012 2:45 AM EST
The Probi probiotic company, which is listed on the Nasdaq OMX Nordic Exchange Stockholm, has gained a new industrial shareholder in the German company Symrise. Symrise has acquired a total of 1,102,301 shares, corresponding to 11.8 % of the capital and 12.1 % of the voting rights in the company, making it Probi’s largest shareholder. This information has been published in a notice disclosing a significant change in...

Probi

Probi is a leading player in probiotic research and the development of efficient and well-documented probiotics. Its research areas include: gastrointestinal tracts, immune system, metabolic syndrome and stress and recov...

View more


  CONTACT  
Probi
Michael Oredsson
  • Michael Oredsson
  • CEO
  • +46(0)70-718 89 30
  • +46(0)46-286 89 23
  •